Informed Prostate Cancer Patient Support

FDA Panel: Thumbs Down for Prostate Cancer Focal Therapy | MedPage Today : Votes 13-2 against novel photodynamic therapy

New study compares long-term side effects from different prostate cancer treatments - Harvard Health Blog - Harvard Health Publishing : Prostate cancer therapies are improving over time. But how do the long-term side effects from the various options available today compare? Results from a newly published study are providing some valuable insights. Investigators at Vanderbilt University and the University of Texas MD Anderson Cancer Center spent five years tracking the sexual, bowel, urinary, and hormonal …

Variation in Inter-institutional Plan Quality When Adopting A Hypofractionated Protocol for Prostate Cancer External Beam Radiation Therapy - International Journal of Radiation Oncology • Biology • Physics : This study quantified plan quality differences across the four cancer centers in XXX(blinded for review) for plans that followed the PROstate Fractionated Irradiation Trial (PROFIT) protocol.

Neoadjuvant and Adjuvant ADT With Dose-Escalated PRT Show Similar Outcomes in Prostate Cancer : Neoadjuvant and concurrent androgen-deprivation therapy (ADT) with dose-escalated prostate radiotherapy (PRT) and concurrent and adjuvant ADT plus dose-escalated PRT were found to have no statistically significant differences in biochemical relapse-free survival in patients with localized prostate cancer, according to results of a phase III trial.

Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy - European Urology Oncology : Recurrent metastatic prostate cancer is frequently detected with prostate-specific membrane antigen positron emission tomography in men treated with radiotherapy, before meeting the Phoenix criteria for biochemical recurrence. These compelling findings call for re-evaluation of the Phoenix criteria, as timely detection of recurrences might refine salvage and/or adjuvant therapies.

Why Don't We Have Robot Surgeons Yet? | Design News : Robotic-assisted surgery has been around for decades. But how long until your next surgeon is a machine?

Apalutamide Benefit Sustained in mCSPC Regardless of Next Therapy : Previous trial results showed signficant improvements in radiographic PFS and OS from adding apalutamide to ADT. The FDA recently approved the drug for metastatic castration-sensitive prostate cancer.